m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01800)
Name
Methotrexate gamma-L-proline-hydroxamic acid
Synonyms
CHEMBL388879; methotrexate gamma-L-proline-hydroxamic acid
    Click to Show/Hide
Status
Investigative
Structure
Formula
C25H30N10O6
InChI
1S/C25H30N10O6/c1-34(12-14-11-28-21-19(29-14)20(26)31-25(27)32-21)15-6-4-13(5-7-15)22(37)30-16(24(39)40)8-9-18(36)35-10-2-3-17(35)23(38)33-41/h4-7,11,16-17,41H,2-3,8-10,12H2,1H3,(H,30,37)(H,33,38)(H,39,40)(H4,26,27,28,31,32)/t16-,17-/m0/s1
InChIKey
UYVVHTPVCDOQRA-IRXDYDNUSA-N
PubChem CID
44428667
TTD Drug ID
D01HKU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-2 (MMP-2)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [2], [3]
Matrix metalloproteinase-9 (MMP-9)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [2], [4]
References
Ref 1 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 2 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. doi: 10.1016/j.bmc.2006.11.017. Epub 2006 Nov 14.
Ref 3 RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.
Ref 4 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.